The ever-growing perception of cancer stem cells (CSCs) as a plastic state rather than a
hardwired defined entity has evolved our understanding of the functional and biological …

Pancreatic cancer is one of the most aggressive and lethal malignancies. Despite
remarkable progress in understanding pancreatic carcinogenesis at the molecular level, as …

Resistance to conventional therapy and early distant metastasis contribute to the
unsatisfactory prognosis of patients with pancreatic cancer. The concept of cancer stem cells …

Cancer stem cells (CSC) have been identified in an ever-increasing number of human
malignancies on the basis of their ability to recapitulate tumors in the ectopic setting and …

Over the past decade, the cancer stem cell (CSC) concept in solid tumors has gained
enormous momentum as an attractive model to explain tumor heterogeneity. The model …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer,
has a median overall survival of 6–12 months and a 5-year survival of less than 7%. While …

Pancreatic cancer (PC) has been one of the deadliest of all cancers, with almost uniform
lethality despite aggressive treatment. Recently, there have been important advances in the …

Pancreatic cancer stem cells (CSCs) have been first described in 2007 and since then have
emerged as an intriguing entity of cancer cells with distinct functional features including self …

Pancreatic cancer is one of the most aggressive cancers worldwide due to the resistances to
conventional therapies and early metastasis. Recent research has shown that cancer stem …

Pancreatic cancer continues to be a malignancy with few therapeutic options. The majority of
patients that present for an evaluation have locally advanced or metastatic disease that is …